Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
CC transcript
Quarterly results
Director departure
Inv. presentation
NEOGENOMICS INC (NEO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "NeoGenomics Reports Second Quarter 2023 Results"
05/08/2023 8-K Quarterly results
Docs: "NeoGenomics Reports First Quarter 2023 Results"
02/23/2023 8-K Quarterly results
Docs: "NeoGenomics Reports Fourth Quarter and Full Year 2022 Results"
11/08/2022 8-K Quarterly results
Docs: "NeoGenomics Reports Third Quarter 2022 Results"
08/09/2022 8-K Quarterly results
04/27/2022 8-K Quarterly results
Docs: "NeoGenomics Reports Revenue of $117 Million in the First Quarter"
02/23/2022 8-K Quarterly results
Docs: "NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021"
11/04/2021 8-K Quarterly results
Docs: "NeoGenomics Reports Revenue of $121 Million in the Third Quarter"
08/06/2021 8-K Quarterly results
Docs: "NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter"
02/24/2021 8-K Quarterly results
10/27/2020 8-K Quarterly results
Docs: "NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter"
07/28/2020 8-K Quarterly results
04/28/2020 8-K Quarterly results
Docs: "NeoGenomics Reports 11% Revenue Growth to $106 Million in the First Quarter"
02/27/2020 8-K Quarterly results
10/29/2019 8-K Quarterly results
07/30/2019 8-K Quarterly results
04/30/2019 8-K Quarterly results
Docs: "NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter"
02/19/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "NeoGenomics Reports 17% Revenue Growth to Record $69 Million"
07/24/2018 8-K Quarterly results
Docs: "NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog The Company adopted ASC 606, effective January 1, 2018, using the full retrospective method of adoption. Unless otherwise indicated, all financial results have been restated as if the Company had adopted this standard on January 1, 2017. Ft. Myers, Florida - July 24, 2018 - NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2018."
05/01/2018 8-K Quarterly results
Docs: "NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018 The Company adopted ASC 606, effective January 1, 2018, using the full retrospective method of adoption. Unless otherwise indicated, all financial results have been restated as if the Company had adopted this standard on January 1, 2017. Ft. Myers, Florida - May 1, 2018 - NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter 2018."
02/21/2018 8-K Quarterly results
Docs: "18.7% increase in clinical genetic testing volume • 12.1% increase in consolidated revenue to $67.8 million • 10.9% reduction in average cost per clinical genetic test • Improvement in Gross Margin to 48.9% from 45.1% in Q4 16 • GAAP EPS of $0.03 per share and non-GAAP Adj. Diluted EPS of $0.05 per share Full Year 2017 Highlights: • 16.7% increase in clinical genetic testing volume • 6.0% increase in consolidated revenue to $258.6 million • 11.3% reduction in average cost per clinical genetic test • Improvement in Gross Margin to 46.5% from 45.2% in 2016 • GAAP EPS of per share and non-GAAP Adj. Diluted EPS of $0.13 per share Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the sa..."
10/25/2017 8-K Quarterly results
07/25/2017 8-K Form 8-K - Current report:
04/26/2017 8-K Form 8-K - Current report
02/22/2017 8-K Form 8-K - Current report
10/26/2016 8-K Form 8-K - Current report
07/26/2016 8-K Quarterly results
Docs: "NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 Integration of Clarient acquisition on track and progressing well."
04/27/2016 8-K Quarterly results
Docs: "NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains Company Increases Full Year 2016 Revenue, EPS & Adjusted EBITDA Guidance"
10/23/2013 8-K Quarterly results
Docs: "NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013"
07/31/2013 8-K Quarterly results
Docs: "NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013"
04/25/2013 8-K Quarterly results
Docs: "NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter"
02/19/2013 8-K Quarterly results
Docs: "NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012"
07/29/2010 8-K Quarterly results
Docs: "NeoGenomics Reports Second Quarter 2010 Results Ft. Myers, Florida – July 29, 2010 - NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2010."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy